Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome (TRAPS): a prospective, open-label, dose-escalation study

Key Findings

• ●Etanercept reduced symptoms and inflammatory markers in dose-dependent manner
• ●Did not completely normalise symptoms or acute phase reactants
• ●Long-term efficacy waned; median duration on treatment 3.3 years

Referenced in (1 disease)